Infliximab Treatment of Crohn Disease Ileovesical Fistula

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 10, 2003, Pages 1097-1098

  Game X ^a   Malavaud, B ^b   Alric, L ^b   Mouzin, M ^b   Sarramon, J P ^b   Rischmann, P ^b  

^a CHU RANGUEIL   (France)

^b NONE

Author keywords

Bladder; Crohn disease; Fistula

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOLOGIC AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; HUMAN; ILEOVESICAL FISTULA; INTESTINE FISTULA; MALE; PRIORITY JOURNAL; SIDE EFFECT; TOTAL PARENTERAL NUTRITION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; ILEAL DISEASES; INTESTINAL FISTULA; MALE; URINARY BLADDER FISTULA;

EID: 0242267100     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310004704     Document Type: Article

References (5)

1. McNamara MJ, Fazio VW, Lavery IC, Weakley FL, Farmer RG. Surgical treatment of enterovesical fistulas in Crohn's disease. Dis Colon Rectum 1990;33:271-6.
2. Goldstein F. Look out for toxic effects of mesalamines! J Clin Gastroenterol 2001;32:176-8.
3. Manganiotis AN, Banner MP, Malkowicz SB. Urologic complications of Crohn's disease. Surg Clin North Am 2001;81:197-215.
4. Shanahan F. Crohn's disease. Lancet 2002;359:62-9.
5. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.